2021 marked a year of resilience and a new normal. Thank you for your continued and unwavering support.

---

### Contents

Message from Executive Director Professor John Lim  
1. Centre of Regulatory Excellence (CoRE)  
   - Advisory Board  
   - Leadership  
   - Our Purpose  
2. EDUCATION  
   - Strengthening Regulatory Systems Through Education  
   - Education in Numbers  
   - Regulatory and Health Systems Strengthening  
   - Medical Devices  
   - Graduate Certificate in Health Products Regulation  
   - Supporting Tomorrow’s Leaders  
   - CoRE Conversation with Ms Emer Cooke  
3. THINK TANK  
   - Sir Alasdair Breckenridge Lecture  
   - Health and Regulatory Systems Strengthening  
   - Accelerating Patient Engagement  
   - Digital Health and Vaccines  
   - CoRE Webinar Series: Encouraging Exchange  
4. DEVELOPMENT  
   - The CoRE Campaign  
   - Opportunities to Collaborate in 2022 and Beyond  
   - International Partnerships  
5. PEOPLE  
   - Year Ahead  
   - Faculty Appointments and Visiting Experts  
   - CoRE Team  
   - Contact Us
The second year of the COVID-19 pandemic in 2021 saw a surge of the Delta variant that stretched global health capacities and resources. However, high vaccination rates in many developed countries and roll-out of booster doses helped significantly mitigate the impact on hospitalisation and mortality. In addition to effective vaccines, the biomedical research community also developed two promising oral therapeutics that may reduce the risk of progression to severe illness in COVID-19 patients. The effectiveness of vaccines and the promise of new therapeutics has given countries confidence to cautiously open up and ease restrictions. However, as 2021 ended, the emergence of the highly transmissible Omicron variant posed fresh challenges to populations and economies. This was a stark reminder that if low and middle income countries are unable to equitably receive adequate vaccination coverage, any progress made towards a transition to an endemic state risks being upended across all countries.

In this challenging local and global context, CoRE continued to function and even flourish through predominantly virtual platforms in our education programmes and think-tank activities. This enabled the Centre to reach a wider geographic range of overseas participants than before. Highlights of 2021 included the Inaugural Sir Alasdair Breckenridge lecture delivered by Sir Jeremy Farrar of the Wellcome Trust in a hybrid event that included a moving video tribute to the late Sir Alasdair, the launch of an education fund in his name, and the graduation of the 2020/21 cohort of our Graduate Certificate Programme. We also launched our inaugural medical devices workshops on In Vitro Diagnostics and Software as a Medical Device and two important workshops to facilitate the effective use of Good Reliance Practices by national regulatory authorities. We hosted our third regional multi-stakeholder roundtable on patient engagement after the successful launch of the Coalition to Accelerate Patient Engagement (CAPE) in Asia-Pacific in 2020. We actively contributed our voice and perspectives to pertinent COVID-19 discussions alongside regional and international thought leaders, through our webinar series, collaborative thought pieces, and interviews with various news and media providers.

The experience of the past two years of the pandemic has reinforced the critical need for regulators to move beyond a siloed approach to regulatory systems strengthening and public health emergency responses. There is now an opportunity to forge a new socio-economic-political compact in which well-trained regulatory professionals proactively participate as key and valued partners in helping to address major global health challenges such as this pandemic and future public health emergencies. To be ready for this new landscape, regulators need holistic skills in both regulatory science and the important soft skills to be adept at navigating the wider socio-political terrain and forging collaborative multi-stakeholder networks.

CoRE is committed to nurturing “future-ready” regulatory professionals through our education programmes and playing a major thought leadership role to stimulate wider thinking on the future of health products and systems regulation and policy innovation in the new normal.

Message from Executive Director
Professor John Lim
We would like to express our appreciation to the visionary leaders on the Centre’s Advisory Board. Their strategic guidance and unceasing support since CoRE’s inception has contributed significantly to CoRE’s success.

We are delighted to welcome Dr Yasuhiro Fujiwara and Adjunct Prof John Skerritt as Special Advisors.

Dr Yasuhiro Fujiwara has been Chief Executive of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) since 1 April 2019. He was elected Co-chair of the International Coalition of Medicines Regulatory Authorities (ICMRA) on 1 October 2019.

Adjunct Prof John Skerritt has been Deputy Secretary at the Australian Department of Health since 2012. He has been part of the national leadership of Australia’s response to the COVID-19 pandemic. He also has line responsibility as Head of the Therapeutic Goods Administration, Australia’s medicine, medical devices, cell and tissue and blood regulator, and leads the Australian Office of Drug Control. He is also Co-chair of the ICMRA.
Our Purpose

VISION

To be a leading Centre enhancing regulatory capability and scientific excellence for health products and systems in Asia.

MISSION

To establish regional platforms and networks to grow competencies, enhance collaboration and promote thought leadership in innovative regulatory science and health policy.

STRATEGIC FOCUS

CoRE has established itself as a unique entity advancing regulatory excellence and policy innovation through our education programmes and think tank initiatives. Our focus is primarily on health products but is increasingly extending into wider health policy and systems issues.

REGULATORY & HEALTH SYSTEMS STRENGTHENING

- Strengthen competencies and understanding of regulatory science
- Promote policy innovation and promulgate best practices, such as regulatory convergence and agility
- Create awareness and communicate relevance
- Encourage collaboration and convergence

FOCUS AREAS

- Patient Engagement | Digital Health | Innovative Therapies | Clinical Trials | Vaccines
- Address issues of strong stakeholder demand and interest
- Amalgamate efforts to achieve targeted outcomes
- Create synergy between education programmes and think tank
EDUCATION

Strengthening Regulatory Systems Through Education

Education in Numbers

Regulatory and Health Systems Strengthening

Medical Devices

Graduate Certificate in Health Products Regulation

Supporting Tomorrow’s Leaders

Inaugural CoRE Conversation with Ms Emer Cooke
STRENGTHENING REGULATORY SYSTEMS THROUGH EDUCATION

With the rapid advancements in science and public health measures, keeping updated on innovations, regulatory requirements and processes remains a key component in ensuring preparedness. Ongoing education and training is critical for continuous professional development and functional regulatory systems. As many have embraced virtual platforms as the main mode of education during these pandemic times, this increased acceptance had facilitated the successful adoption of online programmes for capacity building and systems strengthening.

Through identifying gaps in knowledge and understanding the current trends in regulatory processes, various training activities were conducted by CoRE to help regulatory professionals achieve the confidence and technical skills to carry out their work or transition to new regulatory roles effectively. An empowered workforce will help to increase the standard of regulatory practices and ensure efficient and effective regulatory systems to support public health and economic systems, as witnessed during the course of the COVID-19 pandemic.

As CoRE continues to innovate and leverage on virtual platforms, there are now opportunities to develop more online programmes to cater to various needs of both younger and more experienced regulatory professionals, and increase our scope to cover foundational subjects to new trending topics. This comprehensive approach will help CoRE achieve its role of providing quality education and meeting the needs of regulatory professionals in Asia and other parts of the world.
EDUCATION IN NUMBERS

CAPACITY BUILDING

PARTICIPANTS & ECONOMIES

Training support provided to

>1900 participants* for our modules and workshops

>30 Economies represented

Participant Profile

13% Industry
12% Regulators
3% Academia and Research
71% Government

INTERNATIONALLY RECOGNISED FACULTY

CoRE taps into an international community of active and deeply experienced practitioners of regulatory affairs and biomedical science who provide comprehensive perspectives of the dynamically evolving regulatory and health systems environment. From governments and National Regulatory Agencies to academia and industry, these thought leaders provide culturally relevant examples and real-life experience to the curriculum, in line with Duke-NUS’s hallmark TeamLEAD teaching strategy.

>180 Global expert faculty engaged with our participants

>70 Organisations partnered to provide real-world practice and application

*including those who have attended more than one module
REGULATORY AND HEALTH SYSTEMS STRENGTHENING

Understanding the needs of the regulatory ecosystem in Asia, CoRE expanded its education activities to include medical devices and technology, to facilitate patients’ access to health products as well as the important issue of appropriately applying Good Reliance Practices in differing contexts. The recognition of CoRE as a trusted provider of quality training has paved collaborations with global organisations in bringing these highly relevant workshops to professionals in this region and beyond.

Good Reliance Practices

Workshop 1
Implementing Reliance Approaches
12 - 14 JULY 2021

Attended by 40 regulators from 15 countries in Asia-Pacific, including ASEAN member states, Mongolia, South Africa and Sri Lanka, this workshop built upon the release of the World Health Organisation (WHO) Good Reliance Practices guidelines and was developed with inputs from numerous regulatory stakeholders. Together with representatives from WHO, senior health officers and regulators discussed the operational and practical implementation of collaborative regulatory processes to improve efficiency and effectiveness, which is urgently required in the current situation of a pandemic.

Workshop 2
Using Reliance Approaches for Product Evaluation
27 - 29 SEPTEMBER 2021

This workshop was the second part of the inaugural initiative to build capacity in regulatory cooperation in Asia and focused on the technical competence required to successfully carry reliance activities across the product life cycle. With 45 regulators across 16 countries as far reaching as Rwanda, experts shared their knowledge on the application of reliance in diverse regulatory functions. The conclusion of this workshop provided a platform to further engage interested countries to implement good reliance practices in their respective agencies.

In collaboration with Singapore’s authority for HTA, the Agency for Care Effectiveness (ACE), and academic experts from the University of Adelaide, 42 participants from local healthcare institutions completed an online self-directed learning module as well as a 3-day workshop of intensive hands-on exercises. The discussions and sharing were enriched by the attendance of senior health officers who made up more than half the class.

In continuing the commitment to enhance regulatory capacity in pharmacovigilance for Asia, this workshop focused on the trends and competencies required for responding to public health emergencies. Helmed by WHO, the Uppsala Monitoring Centre (UMC) and the Health Sciences Authority (HSA), a total of 72 participants (half of whom were regulators from ASEAN member states) attended this workshop. The combination of technical training and facilitated discussions effectively engaged the participants, and allowed better understanding of perspectives from regulators and industry in conducting pharmacovigilance during the current COVID-19 pandemic.
MEDICAL DEVICES

While medical devices form key health products alongside pharmaceuticals, regulations addressing their unique and broad spectrum of risks and challenges have yet to be fully implemented throughout the Asia-Pacific region. To respond to this need for competency and capacity building in both industry and regulatory agencies, CoRE launched its inaugural Medical Device workshops to lay the foundational understanding of regulating such medical innovations.

Regulation of In Vitro Diagnostic Devices (IVDs)

1 - 2 SEPTEMBER 2020

With the recent advances and growing significance of IVDs and precision medicine in a patients’ healthcare journey, this two-day workshop provided an understanding of the principles behind effective regulation of IVDs for informed decision making throughout its lifecycle.

Regulation of Software as a Medical Device (SaMD)

1 - 2 DECEMBER 2020

As the emergence of novel digital health technology tools calls for regulatory oversight specific to SaMD that traditional medical device regulations are unable to cater to, this workshop elaborated on the key regulatory considerations in medical software development as well as relevant standards and guidelines for software verification and validation as a crucial tool for effective governance of such devices.
GRADUATE CERTIFICATE IN HEALTH PRODUCTS REGULATION

Drawing on our strong and globe-wide network of prominent regulatory experts, CoRE played a crucial role in capacity building in the region through education and training workshops spanning various facets and categories of health products.
Continuing to stay relevant in the ever-evolving healthcare landscape, the Duke-NUS Graduate Certificate Programme in Pharmaceutical Regulations was enhanced to incorporate medical devices and technologies into its training curriculum, and is now known by its revised title of the Duke-NUS Graduate Certificate in Health Products Regulations.

While the existing programme has earned a positive reputation for educating and upskilling regulatory and healthcare professionals, CoRE recognises the importance of staying relevant in the flourishing biomedical landscape of Singapore, ASEAN and the Asia-Pacific. Further to this and our stakeholders’ feedback, CoRE has redesigned the curriculum to feature three new modules covering state-of-the-art topics on medical devices, including IVDs and Precision Medicine, Regulation of Digital Health Products as well as Post-market processes for Medical Technologies.

CoRE aims to nurture a generation of future-ready regulatory professionals, who have a holistic understanding of end-to-end regulatory processes and are equipped with valuable skillsets that can adapt to changes in the health and biomedical landscape. With a wider selection of training modules and increased flexibility to attain the Graduate Certificate, CoRE offers participants a comprehensive and well-rounded education programme that facilitates gaining knowledge, communication and decision-making skills, along with networking and collaboration, thereby facilitating the growth of a community committed to health and regulatory excellence.
SUPPORTING TOMORROW’S LEADERS

Increasing Access and Opportunities

Funding support provided to 457 participants with scholarships for our modules and workshops.

113 Participants granted scholarships for our Graduate Certificate modules.

12 Economies represented.

Participants from:
- Brunei
- People’s Republic of China
- Indonesia
- Malaysia
- Philippines
- Thailand
- Cambodia
- Indonesia
- Laos PDR
- Myanmar
- Papua New Guinea
- Vietnam

The support from the following partners allow regulatory professionals from both NRAs and industry to participate in CoRE’s Graduate Certificate in Health Products Regulation, augmenting competency enhancement programmes and organisational capacity building efforts.

ASEAN Regulators

Tuition Support Scholarship Scheme

Established in 2018 to support staff from Ministries of Health and NRAs of ASEAN Member States to attend CoRE’s Graduate Certificate Programme.

Australian Indo-Pacific Regulatory Strengthening Program (RSP)

RSP seeks to improve partner countries’ regulatory capacity and hence lead to accessing better and safer medical products. CoRE has been engaged as an official training partner since 2019 and the RSP supports regulators from partner countries to attend CoRE’s Graduate Certificate Programme.

Developing Countries

Vaccine Manufacturers Network (DCVMN)

DCVMN is a public-health-driven international alliance of manufacturers, working to strengthen vaccine manufacturers through various initiatives, one of which is professional training programmes. Since 2019, DCVMN supports their members’ professional development through attending CoRE’s Graduate Certificate and Online Programmes.

Dr Kongchack Phommachack

Technical officer

Drug and Medical Devices Control Division

Food and Drug Department

Ministry of Health, Lao PDR

“Through CoRE’s initiatives to aid in the professional growth of regulators, I am grateful to be a recipient of the CoRE-RSP scholarship, which enables me to broaden and develop my knowledge of health products regulation, through the comprehensive and up-to-date Graduate Certificate programme. More importantly, the modules allow me to share the valuable knowledge gained with colleagues in my home country, which will improve our revisions and functions in our occupational capacities and ultimately benefit patients.”
CoRE instituted a new series entitled CoRE Conversations featuring a one hour ‘fireside chats’ with outstanding global leaders in health products and health systems regulation and policy on their professional paths and experiences that have led them to their successful careers. Aligned with our education strand, this series is a career development initiative, to provide alumni and attendees with the opportunity to hear from the best on their career paths.

INAUGURAL CoRE CONVERSATION
WITH MS EMER COOKE

15 NOVEMBER 2021

We were honoured that Ms Emer Cooke, Executive Director of the European Medicines Agency (EMA), launched this series. In an enlightening and inspiring discussion with Prof John Lim, Ms Cooke talked about her significant professional milestones and shared important perspectives on the international regulatory landscape before, during and beyond the pandemic.

Over 200 people registered on Zoom and LinkedIn Live, comprising participants and alumni of our education offerings based in Singapore and the Asia-Pacific, in addition to a wider international audience. Dr Cooke readily addressed queries posed by the audience regarding her background, formative education and how it shaped her career in addition to sharing her deep knowledge of scientific, communication and socio-cultural issues.

She concluded with her ongoing aspirations and ambitions which could be a useful guide to inspire regulatory professionals in their career choices and also to grow as leaders.

“**My advice to whoever is looking to work towards a career in medicines regulation and global public health: be open to opportunities, including opportunities abroad, be brave, be adaptable, but remain true to yourself.**
THINK TANK

- Sir Alasdair Breckenridge Lecture
- Health and Regulatory Systems Strengthening
- Accelerating Patient Engagement
- Digital Health and Vaccines
- CoRE Webinar Series: Encouraging Exchange

Click to read
The 2021 inaugural Sir Alasdair Breckenridge Lecture was delivered by Professor Sir Jeremy Farrar, Director of the Wellcome Trust on the topic of “Science, Innovation and Society”. Sir Jeremy highlighted the importance and inter-connectedness of these three themes in the context of COVID-19. This was very apt as the Lecture Series was launched during the pandemic as a hybrid event with a small in-person gathering in Singapore and a large online international audience. The Guest-of-Honour was A/Prof Kenneth Mak, Director of Medical Services at Singapore’s Ministry of Health.

Further to this, CoRE colleagues authored an article that was published in Clinical Pharmacology & Therapeutics. The article reflects on our four key take-aways from Sir Jeremy’s inaugural lecture that will stand us in good stead for the current COVID-19 pandemic and as we prepare for other global health challenges ahead.

Following the inaugural lecture, Dr Margaret Hamburg, Chair of CoRE introduced the Alasdair Breckenridge Fund which will provide study awards for regulatory and healthcare professionals from South-East Asia and Asia-Pacific national regulatory authorities and ministries of health to attend courses tenable at CoRE.

In keeping with Sir Alasdair’s interest in promoting regulatory capacity building and professional excellence, the lecture was organised in conjunction with the 2020/21 graduation ceremony of CoRE’s Health Products Regulation Graduate Certificate Programme, to celebrate the achievements of the graduating cohort and affirm their commitment to pursuing regulatory excellence.
The COVID-19 pandemic brought to greater attention the importance of robust and agile health and regulatory systems. Building on our strength and initial focus on health products regulation and regulatory system strengthening, CoRE has expanded into exploring issues related to global health, health policies, and health systems, especially where regulation can play an enabling role.

CoRE actively promoted and explored issues related to regulatory cooperation, convergence, reliance and recognition, agility, and how regulatory excellence can play an enabling role to facilitate responsive access to health products.

Sannie Siaw Foong Chong, Mirinea Kim, Michelle Limoli, Eric Obscherning, Patricia Wu, Lila Feisee, Nobumasa Nakashima & John C. W. Lim

Measuring Progress of Regulatory Convergence and Cooperation Among Asia-Pacific Economic Cooperation (APEC) Member Economies in the Context of the COVID-19 Pandemic

Developed health policy excellence and generate awareness on important global health issues such as universal health coverage, health security and health equity.

Contributed to the WHO project which aims to conduct a global horizon scan on emerging technologies and trends relevant to global public health, so as to assist member states to engage in building futures-thinking into their strategic health planning frameworks.

Prof John Lim is a member of the USP Council of the Convention and chairs the USP Asia Pacific Regional Chapter which provides member organisations a platform to have targeted exploration of issues related to healthcare and pharmaceutical supply chain.

Contributed expert insights to the initiative set up and funded by Roche but independently driven by experts. The initiative aims to build new, personalised, data-driven and resilient health systems that are ready for the future.
ACCELERATING PATIENT ENGAGEMENT

CoRE has come together with like-minded partners to jointly establish CAPE to advance systematic and meaningful patient involvement in health systems across the Asia-Pacific region. CAPE is a multistakeholder partnership hosted at Duke-NUS Medical School. This platform provides an effective, neutral and safe engagement channel for raising awareness, convening and building capacity for patient engagement among all stakeholders in healthcare delivery, health products development and regulation, and HTA.

CAPE Multi-Stakeholder Roundtable: Embedding Patient Engagement for Sustainable Health Systems
7 October 2021

In partnership with Rainbow Across Borders, the Milken Institute, Patient Focused Medicines Development and SDGHI, over 50 participants attended the third regional multi-stakeholder roundtable on Patient Engagement, themed “Embedding Patient Engagement for Sustainable Health Systems”. This year’s virtual meeting and discussion focused on the potential of patient engagement to improve health systems and ways to optimise sustainability through patient-centric organisational cultures, patient involvement in HTA, and effective use of patient experience data.

Dialogue with the Agency for Care Effectiveness (ACE) Consumer Engagement & Education (CEE) Team: The Future of Patient and Public Involvement in HTA in Singapore
18 November 2021

ACE is the national HTA agency in Singapore, reviewing clinical and economic evidence to determine how well health technologies (such as drugs, vaccines and medical devices) work in relation to how much they cost. In 2021, the CEE team was set up at ACE to help patients, carers and the public become involved in the work conducted by ACE. CoRE and ACE partnered to host the first dialogue with over 70 members of patient and volunteer organisations in Singapore to introduce them to HTA, the work of ACE, and how they can be involved in HTA processes.

Engagement with the wider Patient Engagement community

CAPE has also participated in regional and global events related to Patient Engagement, sharing our perspective from Singapore and the Asia-Pacific context with an emphasis on health products development and access and health policy. Events where CAPE participated as speaker and/or panelist include:

- Lymphoma Coalition Global Summit (October)
- The Singapore Experience Exchange with Patient Organisations (SEEPO) (October)
- Asia Pacific Patients Congress (November)
- Milken Institute Partnering for Patients Forum (December)

How does patient engagement support sustainable health systems?

What more can be done to enhance patient engagement?

ACE is the national HTA agency in Singapore, reviewing clinical and economic evidence to determine how well health technologies (such as drugs, vaccines and medical devices) work in relation to how much they cost. In 2021, the CEE team was set up at ACE to help patients, carers and the public become involved in the work conducted by ACE. CoRE and ACE partnered to host the first dialogue with over 70 members of patient and volunteer organisations in Singapore to introduce them to HTA, the work of ACE, and how they can be involved in HTA processes.
The rapid advancement of information and communications technologies and the corresponding digitalisation of communities around the world present great opportunities in helping the world achieve better health outcomes through digital health solutions.

**CoRE closed-door Roundtable: Enabling Digital Health Adoption in Asia-Pacific**

In partnership with Roche, CoRE convened a closed-door roundtable to bring together regulators, policy makers, industry, and other stakeholders in the Asia-Pacific to initiate a broad-based dialogue on Digital Health adoption in the region. Healthcare data policies, data security, and cybersecurity, and digital health regulation were identified as key enablers of digital health adoption. A comprehensive whitepaper based on the roundtable was released in May 2021 with added supplementary information.

**Speaking Engagements**


**VACCINES**

Vaccines was a common topic of great interest for both health professionals and the general public as it became apparent that they will play a significant part in the fight against COVID-19. Discussions, collaboration, and understanding focused on issues ranging from accelerated development, regulatory agility, and emergency approvals – all important issues for promoting equitable access as well as to prevent spread of misinformation.

Prof John Lim explained how the approval of the COVID-19 vaccines was expedited and how decades of work behind the scenes have positioned regulators to respond both rapidly and rigorously to outbreaks.

**External Speaking Engagements and Platforms**

- CoRE article in Asian Scientist: Rapid, Rigorous and Robust: How Singapore Approved Its COVID-19 Vaccines
- APEC article in Asian Scientist: Rapid, Rigorous and Robust: How Singapore Approved Its COVID-19 Vaccines

**CoRE webinar: Safety signal detection and analysis for COVID-19 vaccines at the Uppsala Monitoring Centre**

CORE WEBINAR SERIES: ENCOURAGING EXCHANGE

As the pandemic gave rise to uncertainties about the current state and the future of healthcare, the demand for expert opinion on the latest developments, regulatory efforts and innovations grew. In response, CoRE presented a series of live webinars, to share key insights and perspectives of leading healthcare and regulatory professionals on COVID-19 topics pertinent to Singapore, East Asia, and the rest of the world.

COVID-19 Vaccines - Global Solidarity to Enable Access to Vaccines During a Pandemic
4 FEBRUARY 2021

Key experts representing regulators, NGOs, industry and patient advocates shared their perspectives on how to facilitate transition from emergency use authorisation to full authorisation of COVID-19 vaccines, ensure equitable access and bolster public trust and confidence in vaccines.

Infrastructure to Facilitate Access to Advanced Therapies
24 JUNE 2021

Recent innovations in medical care include cell, tissue and gene therapies, which reflect the advances in clinical sciences and align to the new paradigm of precision medicine. This webinar discussed aspects of facilitating access to advanced therapies, ranging from health system policies, manufacturing facilities, regulations, to healthcare professionals and industry.

Managing Antimicrobial Resistance in Asia: Identification and Implementation of Breakthrough Solutions
29 OCTOBER 2021

Antimicrobial resistance has been recognised by WHO to be a priority public health issue that may be the next major threat to healthcare systems globally. This webinar brought together experts from industry, academia, and government agencies to understand the efforts to address antimicrobial resistance in Asia, and what practical steps can be taken to prepare our healthcare systems.

Smart Regulations in Context of Singapore Food Agency’s Food Safety System
8 AUGUST 2021

This presentation provided an overview of the Singapore Food Agency’s (SFA) 3 principle considerations underpinning Singapore’s food safety system and how these enable SFA to practice smart regulations for food safety and facilitate regulatory innovations such as Singapore being the first country in the world to approve a cell-cultured meat product.
Development

The CoRE Campaign

Opportunities to Collaborate in 2022 and Beyond

International Partnerships
Enabling a World Where Everyone Has Access to Good, Safe, and Effective Health Products

To continue in our mission and effect sustained, meaningful change as a leading education and think tank hub in Asia-Pacific, The CoRE Campaign #Thankstoyou has been established. We welcome unrestricted support through the Regulatory Excellence Fund and current-use commitments for study awards through the Alasdair Breckenridge Fund, established in memory of CoRE’s inaugural Chairman.

This fund will play an important role in enabling the Centre to sustainably address region-wide issues, explore new opportunities for innovation and impactful change, and promote long-lasting cooperative solutions in a time where regulatory agility, convergence, and reliance are key.

Contributions will facilitate meaningful regulatory behavioural changes, by allowing the Centre to convene thought leaders and innovators to generate roadmaps and champion ideas that advance regulatory practice including new emerging topics. Contributions to this fund will also continue to elevate the region’s regulatory capabilities by enabling the Centre to constantly enhance education programmes, as well as address new needs and imbue future readiness among the region’s regulatory and healthcare professionals, academics and researchers.

In keeping with the late Professor Sir Alasdair Breckenridge’s vision and interest of promoting professional excellence, this fund is established to further regulatory capacity building through study awards tenable at CoRE.

Current-use contributions to the Alasdair Breckenridge Fund will support and finance healthcare professionals from national regulatory authorities, ministries of health, and related organisations in ASEAN and Asia-Pacific to enrol in courses run by CoRE. This will enhance their professional development and strengthen the regulatory capacity of their organisations.

GIVE NOW
At CoRE, we work closely with a diverse network of partners from international and regional organisations to promote capacity development and innovation through strategic multi-stakeholder partnerships and collaborations. Leveraging on our expertise and network, we strongly support our stakeholders in driving scientific and regulatory excellence, policy innovation and leadership. Our platform offers many exciting possibilities and collaboration opportunities to engage with key thought leaders, decision makers, and like-minded individuals in the ecosystem.

CoRE looks forward to partner with organisations and associations that see value in our work and would like to collaborate with us. We welcome you to connect with us and become a partner of CoRE. For more information on the various collaboration opportunities and to explore possible partnership engagement, please contact us.

CoRE cultivates multi-stakeholder partnerships and offers a diverse range of collaboration opportunities.

### Online Training Programme
CoRE recognises the evolving training needs in the region and offers comprehensive high quality online programmes to suit the competency needs among regulatory professionals. CoRE is developing an online course on Vaccines and will continue to offer more online programmes. Exciting new opportunities for Executive Certificate courses are also in the pipeline.

### Bespoke workshop
Bespoke training workshops are a valuable asset to our education offerings and provides customisable learning experiences for our students CoRE convenes various in country and regional workshops on topics including Good Reliance Practice, Medical Device Regulations, and many more.

### CoRE Scientific Conference
The CoRE Conference platform provides immense potential for engaging with experts and leaders across the globe. Building on the success of past CoRE Scientific Conferences, the 2022 CoRE Scientific Conference will be centered on the theme of "Patients as Partners for Sustainable Health Systems" and regarded as the first of its kind rooted in Asia to provide a unique multi-stakeholder platform to share insights, experiences, and best practices on patient engagement and advance systematic and meaningful patient involvement in health systems across the Asia-Pacific region. CoRE offers sponsorship opportunities for you to be a part of this conference and position yourself as a key thought leader and showcase your expertise.

### Digital Health Webinars & Symposium
A series of webinars, symposium and publication on Digital Health topics is in the pipeline for 2022, deep diving into and raising awareness on issues related to data collection, quality, validation, and security that were highlighted as key to progressing the use of digital health initiatives in the APAC region.

### Patient Engagement Roundtable
While CoRE convened a series of regional roundtables on Patient Engagement in the past years, this year there is a country specific initiative to host a Singapore centred roundtable meeting for a deeper engagement beyond our regional approach, as part of the multi-stakeholder partnership CAPE.

### Think Tank
CoRE Scientific Conference
INTERNATIONAL PARTNERSHIPS

Working towards regulatory excellence is never an individual endeavour, nor can it be achieved alone. CoRE is honoured to have the opportunity to collaborate and journey with like-minded and mission-driven academic, regulatory and health organisations locally and across the globe. As we collectively set our sights on strengthening systems and building competency through regulatory cooperation and reliance, together, we can realise a world where everyone has access to safe, quality and effective health care.
CoRE: People

- Year Ahead
- Faculty Appointments and Visiting Experts
- CoRE Team
- Contact Us
2022 will be an exciting year, not just for the Centre, but for all who participate in CoRE’s initiatives as well. Guided by our forward-looking 2025 Strategy, we have launched new and improved Graduate Certificate modules and collaborative workshops to look forward to, in addition to opportunities to assemble even more policy makers, regulators, industry members and healthcare providers at our roundtable discussions and think-tank activities.

YEAR AHEAD

We look forward to meeting you at our upcoming events in 2022!

CoRE Scientific Conference

Sir Alasdair Breckenridge Lecture
2022 Lecturer: Dr Penny Heaton

DIA-CoRE Conference

CoRE Conversation

Launch of Online Programme in collaboration with DxD
The Centre would like to show our appreciation to our adjunct faculty, visiting experts, and workshop faculty from NRAs, government agencies, international companies, and industry associations around the world. They collectively bring together an extraordinary wealth of wisdom and real-world experience as they continue to be extensively involved through their contributions and dedication to building regulatory and healthcare excellence across the region and globally.

FACULTY APPOINTMENTS

A/Prof Hsu Li Yang  
Vice Dean (Global Health) & Programme Leader (Infectious Diseases)  
NUS Saw Swee Hock School of Public Health

A/Prof Daniel Ting  
Director  
Cluster AI Program  
Singapore Health Service (SingHealth)

Adj A/Prof Chan Cheng Leng  
Group Director  
Health Products Regulation Group  
Health Sciences Authority Singapore

Adj A/Prof Sidney Yee  
Founding Chief Executive Officer  
Diagnostics Development Hub  
Inaugural Co-Chair  
ASEAN DxD Initiative

Adj A/Prof Raymond Chua  
Deputy Director  
Medical Services  
Health Regulation Group  
Assistant Commissioner  
Cybersecurity  
Ministry of Health, Singapore

Adj A/Prof Kellathur Srinivasan  
Director  
Policy, Research and Evaluation Division  
Ministry of Health, Singapore

Adj A/Prof Cynthia Sung  
Portfolio & Platform Lead  
Translational Sciences  
Global Health  
Bill & Melinda Gates Medical Research Institute

Adj A/Prof Sidney Yee  
Founding Chief Executive Officer  
Diagnostics Development Hub  
Inaugural Co-Chair  
ASEAN DxD Initiative

Adj A/Prof Clive Tan  
Adjunct Assistant Professor  
Saw Swee Hock School of Public Health
## VISITING EXPERTS

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Fouad Atouf</td>
<td>Vice President, Global Biologics, The United States Pharmacopoeial Convention (USP)</td>
</tr>
<tr>
<td>Dr Gregory Daniel</td>
<td>Global Head of Public Policy, Eli Lilly and Company</td>
</tr>
<tr>
<td>Dr Jean-Christophe Delumeau</td>
<td>CoRE Head, Regulatory Affairs, Duke Translational Medicine Institute, Duke University</td>
</tr>
<tr>
<td>Prof Hans-Georg Eichler</td>
<td>Head, Pharmacovigilance Policy Strategy (Global), Bayer</td>
</tr>
<tr>
<td>Dr Rominder Singh</td>
<td>Head, Regulatory Affairs, Asia Global Regulatory Affairs International, Pfizer</td>
</tr>
<tr>
<td>Dr Tippi Mak</td>
<td>Board Member, Vaccine &amp; Infectious Disease Organization - International, University of Saskatchewan, Canada, Medical Affairs Lead, Infectious Diseases &amp; Vaccines Janssen</td>
</tr>
<tr>
<td>Dr Sethuraman Rama</td>
<td>Director, Medical Devices Branch, Health Sciences Authority Singapore</td>
</tr>
<tr>
<td>Dr Valerio Reggi</td>
<td>Consultant, Drug Regulatory Matters &amp; Pharmaceutical Policy</td>
</tr>
<tr>
<td>Dr Adelheid Schneider</td>
<td>Head, Regulatory and Quality Asia Pacific, Roche Diagnostics Asia Pacific</td>
</tr>
<tr>
<td>Prof Stuart Walker</td>
<td>Founder, Centre for Medicines Research International Limited, Pharmaceutical Medicine University of Wales, Cardiff</td>
</tr>
<tr>
<td>Mr John Wilkinson</td>
<td>Chair, Global Medical Devices Nomenclature Agency, Novartis Asia Pacific</td>
</tr>
<tr>
<td>Dr Anne Cook</td>
<td>Expert Quality Assessor, UK Medicines &amp; Healthcare, The United States Pharmacopoeial Convention (USP), Regulatory Agency</td>
</tr>
<tr>
<td>Prof Kenneth Hartigan-Go</td>
<td>Head, Stephen Zueilig, School of Development Management, Asian Institute of Management</td>
</tr>
<tr>
<td>Dr Lam Siu Ping</td>
<td>Director, Licensing Division, UK Medicines and Healthcare, Regulatory Agency</td>
</tr>
<tr>
<td>Dr Leung Pak-yin</td>
<td>Former Chair Executive, Hospital Authority, Hong Kong Special Administrative Region</td>
</tr>
<tr>
<td>Dr Kerwin Low</td>
<td>Vice President, Regulatory Affairs, Emerging Markets, Takeda Pharmaceuticals International</td>
</tr>
<tr>
<td>Mr Michael Gropp</td>
<td>Former Chair, RAPS, Global Advisory Council</td>
</tr>
<tr>
<td>Dr Wassim Nasabeh</td>
<td>Vice President &amp; Global Head, Policy &amp; International Operations, Roche Regulatory Agency</td>
</tr>
<tr>
<td>Dr Moheb Nasr</td>
<td>Principal, Nasr Pharma Regulatory Consulting (NPRC)</td>
</tr>
<tr>
<td>Dr Poh Weijie</td>
<td>Global Project Manager, Healint Pte. Ltd</td>
</tr>
<tr>
<td>Mr Rajakanth R</td>
<td>Principal Consultant, Manifeste LLP, Executive Director, Rainbow Across Borders Ltd</td>
</tr>
<tr>
<td>Mr Mrung Chai Waa</td>
<td>Executive Director, Regulatory Affairs, Asia Global Regulatory Affairs, Indonesia</td>
</tr>
<tr>
<td>Mr Leung Pak-yin</td>
<td>Regulatory Affairs, Asia Global Regulatory Affairs, Roche</td>
</tr>
<tr>
<td>Mr John Wilkinson</td>
<td>Global Medical Devices Nomenclature Agency, Novartis Asia Pacific, Regulatory Agency</td>
</tr>
<tr>
<td>Dr Anne Cook</td>
<td>Expert Quality Assessor, UK Medicines &amp; Healthcare, The United States Pharmacopoeial Convention (USP), Regulatory Agency</td>
</tr>
<tr>
<td>Prof Kenneth Hartigan-Go</td>
<td>Head, Stephen Zueilig, School of Development Management, Asian Institute of Management</td>
</tr>
<tr>
<td>Dr Murray Lumpkin</td>
<td>Deputy Director, Integrated Development Lead, Global Regulatory Systems Initiatives, Bill &amp; Melinda Gates Foundation</td>
</tr>
<tr>
<td>Dr Tomas Salmonsan</td>
<td>Partner, Consilium Salmonsan &amp; Hemmings, Former Chair, Committee for Medicinal Products for Human Use, European Medicines Agency</td>
</tr>
<tr>
<td>Dr Valerio Reggi</td>
<td>Consultant, Drug Regulatory Matters &amp; Pharmaceutical Policy</td>
</tr>
<tr>
<td>Dr.-Ing Stephan Roenninger</td>
<td>Adjunct Assistant Professor, George Washington University, Quality External Affairs, Amgen (Europe)</td>
</tr>
<tr>
<td>Dr Tomas Salmonsan</td>
<td>Partner, Consilium Salmonsan &amp; Hemmings, Former Chair, Committee for Medicinal Products for Human Use, European Medicines Agency</td>
</tr>
<tr>
<td>Dr Settharaman Rama</td>
<td>Director, Medical Devices Branch, Health Sciences Authority Singapore</td>
</tr>
<tr>
<td>Dr Valerio Reggi</td>
<td>Consultant, Drug Regulatory Matters &amp; Pharmaceutical Policy</td>
</tr>
<tr>
<td>Dr Kerwin Low</td>
<td>Vice President, Regulatory Affairs, Emerging Markets, Takeda Pharmaceuticals International</td>
</tr>
<tr>
<td>Mr Michael Gropp</td>
<td>Former Chair, RAPS, Global Advisory Council</td>
</tr>
<tr>
<td>Dr Wassim Nasabeh</td>
<td>Vice President &amp; Global Head, Policy &amp; International Operations, Roche Regulatory Agency</td>
</tr>
<tr>
<td>Dr Moheb Nasr</td>
<td>Principal, Nasr Pharma Regulatory Consulting (NPRC)</td>
</tr>
<tr>
<td>Dr Poh Weijie</td>
<td>Global Project Manager, Healint Pte. Ltd</td>
</tr>
<tr>
<td>Mr John Thornback</td>
<td>Senior Advisor, Diagnostics Development Hub</td>
</tr>
</tbody>
</table>
CoRE’s success over the past years would not be possible without the commitment and dedication of our CoRE Team and we look forward to working with you in 2022.